EVALUATION OF NEW DRUGS: A CHANGING LANDSCAPE FOR OLDER ADULTS AND DIVERSE POPULATIONS

Symposia

  • Date:
  • Time: 10:30am - 11:30am
  • Track: Research
  • CME/CE: 1.0
  • Type: In-Person

Moderator: Joseph Ouslander, MD
This symposium will address the gaps in enrollment of older adults and older adults of minority status in clinical trials, the need for this information and the evolving landscape trying to fill this gap, and the important role that clinicians can play to increase participation in clinical trials of new medical therapies. Learning Objectives: (1) discuss the gaps in drug evaluation in older clinical populations-- especially the areas of greatest needs; (2) describe the evolving goals for age-related and diversity-related requirements for trial enrollment and reporting; and (3) review the clinical trial design and evaluation process as it relates to improving participation of older adults and more diverse clinical trial populations-- both in the US and internationally.

Current Status of Inclusion of Older Groups in Evaluations of New Medical Therapies: The Gaps
Janice B. Schwartz, MD

Recommendations to Close the Gaps: NASEM
Sharon K. Inouye, MD, MPH

Recommendations to Close the Gaps: The FDA Perspective
Robert J. Temple, MD

International Perspective on Improving Evaluation of New Drugs in Older Adults: The
European Geriatric Medicine Society 
Antonio Cherubini, MD, PhD

An International Perspective: International Union of Basic and Clinical Pharmacology
Sarah N. Hilmer, MBBS, PhD, FRACP